Search Results for: EXECUTIVE INTERVIEW The Integration of
Articles
EXECUTIVE INTERVIEW – BD Integrated Systems: From Innovation to Integration November 12, 2018
Theresa Bankston, PhD, Director of the Technical Services group for BD Medical – Pharmaceutical Systems, discusses the advantages of using an integrated system for complex drug-device combination products.
EXECUTIVE INTERVIEW – The Integration of Bend Research With Capsugel Dosage Form Solutions (DFS) June 4, 2014
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics August 31, 2022
Bill Hartzel, Senior Vice President and Head of CDMO Business, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
EXECUTIVE INTERVIEW – Catalent: Developing & Delivering Billions of Doses of Drugs Every Year June 1, 2022
Alessandro Maselli, President and Chief Operating Officer of Catalent, talks about his company’s unique approach to drug development partnerships as he prepares to become the company’s new President and Chief Executive Officer on July 1, 2022.
EXECUTIVE INTERVIEW – PCI Pharma Services: Broadening Our Biologics Footprint, Together May 2, 2022
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
EXECUTIVE INTERVIEW – Syner-G BioPharma: A Track Record of CMC Excellence April 4, 2022
Prabu Nambiar, PhD, Founder and CEO Syner-G, discusses the company’s evolution, its approach to CMC, and the future of the organization.
EXECUTIVE INTERVIEW – inVibe: Changing the Research Game With Voice April 4, 2022
Fabio Gratton, CEO of inVibe, discusses patient-focused drug development (PFDD), his company’s language model, and the value this technology brings to a patient’s treatment journey.
EXECUTIVE INTERVIEW – Celanese: Better Therapeutic Outcomes From Better Drug Delivery March 29, 2021
Laura Brand, Vice President of Celanese’s Medical & Pharmaceutical Business, discusses her company’s drug delivery platform and the value it brings to the industry.
EXECUTIVE INTERVIEW – BiologIC Technologies: The Future Microsoft for the Biorevolution January 13, 2021
Richard Vellacott, CEO of BiologIC Technologies, discusses his company’s unique technology and its applications in the future of medicine and wider fields of synthetic biology.
EXECUTIVE INTERVIEW – Adare Pharmaceuticals: A Virtual Acquisition is Possible June 3, 2020
Ajay Damani, VP of Pharmaceutical Technologies Business Unit, Adare, and Maria Flynn, President and CEO, Orbis, discuss how both companies will benefit from the acquisition, future product development, and the challenges of a virtual acquisition.
EXECUTIVE INTERVIEW – Cambrex: Providing Big Value in the Small Molecule Outsourcing Market October 1, 2019
Simon Edwards, President, CDMO Sales & Marketing at Cambrex, discusses the biggest trends in the small molecule outsourcing market.
EXECUTIVE INTERVIEW – SHL Group: Expansion Driven by Our Partners August 27, 2018
Taras Seniuch, Director of Business Development at SHL’s contract manufacturing organization, SHL Pharma, talks about his company’s unique service offering for its partners.
EXECUTIVE INTERVIEW – Lonza Pharma & Biotech: Taking on the Next Challenges in Small Molecules November 20, 2017
Gordon Bates, Head of Chemical Division at Lonza Pharma & Biotech, shares his perspective about industry needs and how strategic acquisitions are enhancing Lonza’s position as a development and manufacturing partner of choice.
EXECUTIVE INTERVIEW – PCT: Manufacturing the Future of Cell Therapies May 1, 2017
Robert A. Preti, PhD, discusses his company’s critical distinction from most other manufacturing partners, steady growth, and the primary challenges facing the cell therapy industry.
EXECUTIVE INTERVIEW – Capsugel: Choosing the Right Pharmaceutical Design, Development & Manufacturing Partner January 7, 2016
Pharmaceutical companies today increasingly require specialized design, development, and manufacturing partners to help bring new and improved drugs to market....EXECUTIVE INTERVIEW – Patheon: Comprehensive Development & Manufacturing Solutions for the Entire Drug Development Cycle June 1, 2015
Franco Negron, Patheon’s Senior VP of Drug Product Services, discusses his company’s business strategy, two recent acquisitions and integration plans, the role biosimilars play in Patheon’s business, and significant trends driving the pharmaceutical industry over the next few years.
EXECUTIVE INTERVIEW – Parexel: Simplifying the Journey to Market July 3, 2014
Drug Development Executive: Carol Collins, Corporate Vice President, Strategic Partnerships, PAREXEL, clarifies how Strategic Partnerships differ from other outsourcing approaches – and what makes them more effective.
EXECUTIVE INTERVIEW – Gerresheimer: Understanding Customer Requirements March 3, 2014
Drug Development Executive: Andreas Schütte, Member of the Management Board, Plastics & Devices Division, discusses his important role in Gerresheimer’s divisional restructuring process, and how he is convinced the new structure better reflects customer requirements.
SPECIAL FEATURE – Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
SPECIAL FEATURE – Injectable Drug Delivery: New Technologies Deliver Biologics & Differentiate Brands September 12, 2017
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.